Psychedelic Assisted Therapy

Mindspace by Numinus has become a pioneer in Canada in the emerging field of psychedelic-assisted therapy in recent years. Our joining with the Numinus Wellness team in early 2021 means that we now deliver best-in-class, leading-edge mental health solutions nationwide.

In 2019 we hosted one of the first training programs in Canada for clinicians wanting to learn more about helping their clients work safely with psychedelics, and launched our Psychedelic Harm Reduction and Integration program, and in late 2020 we began offering ketamine-assisted therapy. Our psychedelics team continues to push this discipline forward and facilitate continuing education efforts with a number of partners throughout North America.

Ketamine Treatment

Ketamine Treatment

There is an increasing body of evidence that suggests that the supervised use of ketamine can be effective as a treatment for depression. Ketamine occupies a unique position in the psychedelic landscape from a regulatory perspective and can now be prescribed to address treatment-resistant depression. Mindspace has assembled a multi-disciplinary team of health care professionals in order to offer this service to our clients.

Psychedelic Harm Reduction and Integration

Psychedelic Harm Reduction and Integration

Mindspace holds a harm reduction position in response to the growing public interest in psychedelics to support the mental health and well-being of individuals who intend to or have had psychedelic experiences. While Mindspace neither condemns nor encourages psychedelic use, we believe that with proper education and integration support, the potential benefits of psychedelic use can be increased, and the risks associated with it reduced.

Psychedelic-Assisted Psychotherapy with MDMA and Psilocybin

Psychedelic-Assisted Psychotherapy with MDMA and Psilocybin

Mindspace by Numinus is pleased to be at the forefront of psychedelic-assisted psychotherapy solutions in Canada. Specifically, in light of Health Canada’s revision to its Special Access Program, our medical team is now able to submit applications on behalf of appropriate candidates for potential treatment with psilocybin and MDMA.

Our Team

From the Blog